Today's Hours: 8:00am - 6:00pm

Search

Filter Applied Clear All

Did You Mean:

Search Results

  • Book
    Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith, editors.
    Summary: This book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.

    Contents:
    Intro
    Contents
    1: History of Drug Development for Children with Cancer
    1.1 Introduction
    1.2 Initial Progress
    1.3 Rise of the Cancer Cooperative Groups
    1.4 Impact of Regulation to Improve Safety and Efficacy Federal Laws Providing a Regulatory Framework for Drug Development in Children
    1.5 Indications
    1.6 Summary
    References
    2: Targeted Small Molecule Drug Discovery
    2.1 Introduction
    2.2 Stage Gating
    2.3 Phenotypic Drug Discovery
    2.4 Target-Based Drug Discovery: Considerations for Target Selection/Identification 2.5 Target-Based Drug Discovery: Identifying Chemical Starting Points
    2.6 Hit-to-Lead
    2.7 Lead Optimization
    2.8 Candidate Nomination
    References
    3: An FDA Oncology Perspective of Juvenile Toxicity Studies to Support Pediatric Drug Development
    3.1 Introduction
    3.2 Should a JAS Be Considered?
    3.2.1 ICH S11: Nonclinical Safety Testing in Support of Development of Pediatric Medicines
    3.2.2 ICH S9: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
    3.3 Dinutuximab and Naxitamab
    3.4 TRK Inhibitors
    3.5 Conclusion
    References 4: Design and Statistical Considerations for Early Phase Clinical Trials in Pediatric Oncology
    4.1 Introduction
    4.2 Rule-Based Designs
    4.2.1 Traditional 3 + 3 Design
    4.2.2 Accelerated Titration Design
    4.2.3 Rolling Six Design
    4.3 Model-Based Designs
    4.3.1 Continual Reassessment Method (CRM)
    4.3.2 EWOC and BLRM
    4.3.3 TITE-CRM and TITE-EWOC
    4.4 Model-Assisted Designs
    4.4.1 Modified Toxicity Probability Interval (mTPI) Design
    4.4.2 Keyboard Design
    4.4.3 Bayesian Optimal Interval (BOIN) Design
    4.5 New Designs
    4.5.1 Modified 4 + 4 Design 4.6 Conclusions
    References
    5: Exploratory Clinical Development: From First in Humans to Phase 3 Ready
    5.1 Introduction
    5.2 The Therapeutic Hypothesis
    5.3 Dose and Schedule Determination
    5.4 Clinical Proof of Concept (PoC)
    5.5 Putting It All Together: Combined Phase 1-2 Studies
    5.6 A Role for Pediatric Cancer in Exploratory Drug Development
    References
    6: Gene and Cell Therapy: How to Build a BioDrug
    6.1 Introduction
    6.2 BioDrug ToolKit: Cells
    6.2.1 Hematopoietic Stem Cells (HSCs)
    6.2.2 T Lymphocytes
    6.2.3 Natural Killer (NK) Cells
    Digital Access Springer 2022